86 results
Page 2 of 5
8-K
EX-3.1
n3u vk2gt
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:35pm
8-K
EX-1.1
8f4216 aakzv
13 Sep 23
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
5:23pm
424B5
x9ejx3a9tt
13 Sep 23
Prospectus supplement for primary offering
5:19pm
424B5
fi5edc1xlzmbj5e
11 Sep 23
Prospectus supplement for primary offering
4:09pm
8-K
EX-99.1
k8hzy
11 Sep 23
Regulation FD Disclosure
6:05am
DEFA14A
bq9d4mk3grs2vb
27 Apr 23
Additional proxy soliciting materials
4:56pm
8-K
EX-99.1
jyb165bz5v4ohzl
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
8-K
EX-99.1
negca dv88mwrs
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am
424B5
opigntku3e 8xrr
12 Aug 22
Prospectus supplement for primary offering
8:31am
DEFA14A
jd5hojdr0fwkf0vntyc
28 Apr 22
Additional proxy soliciting materials
4:58pm
8-K
EX-1.1
v3jt2d6 d79ehg138l
13 Apr 22
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
4:26pm
424B5
r4sp1uqlodqgg
13 Apr 22
Prospectus supplement for primary offering
4:22pm